More Positive $ISOLF news
ISODIOL INTERNATIONAL ACQUIRES GLOBAL RIGHTS TO PRODUCE PRODUCTS UNDER AN INNOVATIVE DELIVERY SYSTEM PATENT
Isodiol International Inc.'s division, C3 Global Biosciences (C3GBS), has agreed in principle to acquire the rights to become the exclusive worldwide distributor of Advanced Brain Monitoring's (ABM) electroencephalogram (EEG) technology in the phytoceutical field, specifically the cannabis community.
For the last 15 years, ABM has challenged conventional thinking by developing innovative medical devices that provide superior patient experience, lower healthcare costs, and improved quality of care. With this versatile, state of the art wireless EEG system, interpretation of physiological signals across a wide variety of real-world applications are finally here. The EEG system will allow physicians and researchers real-time feedback on the effect of Cannabis products. The EEG device is reimbursable and has designated CPT codes for physicians to submit to health insurance companies.
Andrew Serafini, C3GBS President, says, "The need to fast-track and bring to market therapeutic novel compounds that possess great potential in human diseases have a need for an FDA-approved drug validation technology that should become mandatory. The cannabis industry lacks verification methodologies and C3GBS is excited to bring the EEG technology to the forefront to help further discover the benefits in real time. This will invariably result in evidence-based data gathering to help support and guide the healthcare practitioner."
"This is another monumental step taken by Isodiol and C3GBS to be the global leader in cannabis research, science, innovation, and technology to positively impact patient outcomes. The EEG system offers another diagnostic tool, that is FDA approved, to help understand how cannabis is beneficial to the human body," added Isodiol CEO, Marcos Agramont.
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical-grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry, including commercialization of 99-per-cent-plus-pure, bioactive pharmaceutical-grade cannabinoids, microencapsulations, and nanotechnology for the highest-quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs and expanding its phytoceutical portfolio, and it will aggressively continue international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd. All rights reserved.
